Quick Answer
Telix Pharmaceuticals Ltd reported Research And Development Expense of $171.25 million for the year ending 2025.
- Telix Pharmaceuticals Ltd showed an increase of +33.9% in Research And Development Expense from 2024 to 2025.
- This data is from Telix Pharmaceuticals Ltd's annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Telix Pharmaceuticals Ltd's Research And Development Expense has grown by 112.2%.
- Historical annual values: Fiscal year 2025: $171.25 million | Fiscal year 2024: $127.93 million | Fiscal year 2023: $85.32 million | Fiscal year 2022: $80.69 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: